Unity Bio Restructuring Cuts 30% of Staff, Keeps Focus on Eye Drug

Unity Biotechnology is cutting nearly one third of its staff, a move that comes a month after the biotech’s lead drug candidate failed a mid-stage study in osteoarthritis. South San Francisco-based Unity (NASDAQ: UBX) says that the corporate restructuring announced Tuesday should make the cash that it has left last through mid-2022, when data are […]

ADVERTISEMENT — Advertise With Biotech Networks